Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 6/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5935758 | 0.99 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3MEN1 | |
| SCHEMBL3232467 | 0.85 | ADORA2A (0.73) | ADORA2AADORA2BADORA1ADORA3LMNA | |
| SCHEMBL3229056 | 0.84 | ADORA2A (0.73) | ADORA2AADORA2BADORA1ADORA3LMNA | |
| SCHEMBL27465278 | 0.84 | ADORA2A (0.72) | ADORA2AADORA2BADORA1ADORA3LMNA | |
| SCHEMBL3235950 | 0.81 | ADORA2A (0.69) | ADORA2AADORA2BADORA1ADORA3LMNA | |
| SCHEMBL7441522 | 0.79 | ADORA2A (0.66) | ADORA2AADORA2BADORA3 | |
| SCHEMBL7441532 | 0.79 | ADORA2A (0.66) | ADORA2AADORA2BADORA3 | |
| SCHEMBL5935691 | 0.79 | ADORA2A (1.00) | ADORA2AADORA2BADORA3LMNACYP1A2 | |
| SCHEMBL31228989 | 0.78 | ADORA2A (0.64) | ADORA2AADORA2BADORA1 | |
| SCHEMBL5231865 | 0.77 | ADORA2A (0.64) | ADORA2AADORA2BADORA1ADORA3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114375-A1 | Method for treating cystic fibrosis | THE GOVERNMENT OF THE USA, DEPT OF HEALTH AND HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH | 2003-06-19 | — | — | US | claimed |
| CN-1176648-A | Method for identifying CFTR-binding compounds for activating chloride conductance in animal cells | US HEALTH (US) | 1998-03-18 | — | — | CN | claimed |
| EP-0794963-A2 | A METHOD OF IDENTIFYING CFTR-BINDING COMPOUNDS USEFUL FOR ACTIVATING CHLORIDE CONDUCTANCE IN ANIMAL CELLS | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-09-17 | — | — | EP | claimed |
| WO-1996016084-A2 | A METHOD OF IDENTIFYING CFTR-BINDING COMPOUNDS USEFUL FOR ACTIVATING CHLORIDE CONDUCTANCE IN ANIMAL CELLS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-05-30 | — | — | WO | claimed |
| US-7189717-B2 | Medicinal compositions promoting bowel movement | EISAI CO., LTD. (JP) | 2007-03-13 | — | — | US | disclosed |
| US-20070054876-A1 | Pharmaceutical composition promoting defecation | YASUDA MASAHIRO | 2007-03-08 | — | — | US | disclosed |
| US-20060270674-A1 | Pharmaceutical composition promoting defecation | YASUDA MASAHIRO | 2006-11-30 | — | — | US | disclosed |
| US-20060052404-A1 | Pharmaceutical formulations comprising substituted xanthine compounds | SCICLONE PHARMACEUTICALS, INC. | 2006-03-09 | — | — | US | disclosed |
| CN-1197621-C | Medicinal compositions promoting bowel movement | EISAI CO LTD (JP) | 2005-04-20 | — | — | CN | disclosed |
| EP-1510222-A2 | Medicinal compositions promoting bowel movement | Eisai Co. Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040259865-A1 | Pyrimidone compounds and pharmaceutical compositions containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1448203-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING SUBSTITUTED XANTHINE COMPOUNDS | Sciclone Pharmaceuticals, Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030114375-A1 | Method for treating cystic fibrosis | THE GOVERNMENT OF THE USA, DEPT OF HEALTH AND HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH | 2003-06-19 | — | — | US | disclosed |
| WO-2003037345-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING SUBSTITUTED XANTHINE COMPOUNDS | SCICLONE PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-1283056-A1 | MEDICINAL COMPOSITIONS PROMOTING BOWEL MOVEMENT | Eisai Co., Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-6083954-A | ADMINISTERING PURINE DERIVATIVE | US HEALTH (US) | 2000-07-04 | — | — | US | disclosed |
| US-5877179-A | CYSTIC FIBROSIS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-03-02 | — | — | US | disclosed |
| CN-1176648-A | Method for identifying CFTR-binding compounds for activating chloride conductance in animal cells | US HEALTH (US) | 1998-03-18 | — | — | CN | disclosed |
| EP-0794963-A2 | A METHOD OF IDENTIFYING CFTR-BINDING COMPOUNDS USEFUL FOR ACTIVATING CHLORIDE CONDUCTANCE IN ANIMAL CELLS | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996016084-A2 | A METHOD OF IDENTIFYING CFTR-BINDING COMPOUNDS USEFUL FOR ACTIVATING CHLORIDE CONDUCTANCE IN ANIMAL CELLS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114375-A1 | Method for treating cystic fibrosis | CFTR, ADORA1, ADORA3 | ADORA2A 20/4885ADORA2B 27/4885ADORA1 2/4885 |
| US-20070054876-A1 | Pharmaceutical composition promoting defecation | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA2B 1/4885ADORA1 3/4885 |
| US-20060052404-A1 | Pharmaceutical formulations comprising substituted xanthine compounds | CFTR, XDH, SLC10A1 | ADORA2A 219/4885ADORA2B 325/4885ADORA1 140/4885 |
| US-20040259865-A1 | Pyrimidone compounds and pharmaceutical compositions containing the same | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA2B 4/4885ADORA1 2/4885 |
| US-20060270674-A1 | Pharmaceutical composition promoting defecation | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA2B 1/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.